Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS

被引：59

作者：

Brassat, D

Recher, C

Waubant, E

Le Page, E

Rigal-Huguet, F

Laurent, G

Edan, G

Clanet, M

机构：

[1] Toulouse Univ, Med Ctr, Hop Purpan, Federat Neurol,Dept Neurol, F-31059 Toulouse, France

[2] Toulouse Univ, Med Ctr, Hop Purpan, Dept Haematol, Toulouse, France

[3] Hop Pontchaillou, Dept Neurol, Rennes, France

[4] UCSF, Multiple Sclerosis Ctr, San Francisco, CA USA

来源：

NEUROLOGY | 2002年 / 59卷 / 06期

关键词：

D O I：

10.1212/WNL.59.6.954

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors report a patient with severe secondary progressive MS who responded to mitoxantrone but developed a fatal acute myeloblastic leukemia 15 months after completion of mitoxantrone therapy. Therapy-related acute leukemia (TRAL) in relation with mitoxantrone is rare; this patient was the first case among a cohort of 802 French MS patients treated with mitoxantrone. Nevertheless, this case stresses the need to further evaluate the long-term risk of TRAL in patients with MS who receive mitoxantrone.

引用

收藏

页码：954 / 955

页数：2

相关论文

共 10 条

[1] Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study [J].

Chaplain, G ;

Milan, C ;

Sgro, C ;

Carli, PM ;

Bonithon-Kopp, C .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) :2836-2842

[2] Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria [J].

Edan, G ;

Miller, D ;

Clanet, M ;

Confavreux, C ;

LyonCaen, O ;

Lubetzki, C ;

Brochet, B ;

Berry, I ;

Rolland, Y ;

Froment, JC ;

Dousset, V ;

Cabanis, E ;

IbaZizen, MT ;

Gandon, JM ;

Lai, HM ;

Moseley, I ;

Sabouraud, O .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (02) :112-118

[3]

Edan G, 2001, MULT SCLER, V7, pS14

[4] Secondary leukemias induced by topoisomerase-targeted drugs [J].

Felix, CA .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :233-255

[5]

Goodkin DE, 2001, MULT SCLER S1, V7, pS129

[6]

HARTUNG HP, 1998, MULT SCLER, V4, P325

[7] Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome [J].

Millefiorini, E ;

Gasperini, C ;

Pozzilli, C ;

DAndrea, F ;

Bastianello, S ;

Trojano, M ;

Morino, S ;

Morra, VB ;

Bozzao, A ;

Calo, A ;

Bernini, ML ;

Gambi, D ;

Prencipe, M .

JOURNAL OF NEUROLOGY, 1997, 244 (03) :153-159

[8] Medical progress: Multiple sclerosis. [J].

Noseworthy, JH ;

Lucchinetti, C ;

Rodriguez, M ;

Weinshenker, BG .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :938-952

[9] Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors [J].

Pedersen-Bjergaard, J ;

Andersen, MK ;

Johansson, B .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1897-1898

[10] Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis [J].

Vicari, AM ;

Ciceri, F ;

Folli, F ;

Lanzi, R ;

Colombo, B ;

Comi, G ;

Camba, L .

LEUKEMIA, 1998, 12 (03) :441-442